Matt Spindler
Vice President, Research GigaMune
At GigaMune, we are advancing novel lentivector platforms for efficient in vivo gene delivery of CARs and TCRs to T cells for the treatment of cancer. I lead the translational research efforts, where we are characterizing a highly diverse library of over 160 viral pseudotypes to enable enhanced in vivo gene delivery, while also developing novel CAR and TCR therapeutic payloads targeting tumor antigens. As a cancer survivor, I am deeply motivated to translate these technologies into new therapeutic options for patients.
Seminars
Thursday 30th July 2026
Novel Lentivector Systems for In Vivo CAR & TCR Delivery for Liquid & Solid Tumor Control
11:30 am
- Developing lentivector systems using novel viral pseudotypes for improved in vivogene delivery and possibly enabling patient redosing
- Demonstrating in vivo efficacy of CD19 CAR delivery in liquid tumor models using a novel pseudotype
- Applying this novel lentivector system to the delivery of TCRs in melanoma models, expanding therapeutic reach into solid tumor indications
